Strategic Renewal in Clinical Services
ABL Diagnostics and CDL Pharma have successfully renewed their clinical services agreement with Servier, a prominent French pharmaceutical partner. This multi-year arrangement enhances ABL’s integrated platform, allowing for improved revenue visibility and supporting the Group’s intra-portfolio strategy.
Strengthening Collaborative Frameworks
The renewal reflects ABL Diagnostics’ commitment to a strategic intra-group distribution framework initiated in July 2025. This framework, publicly revealed in October 2025, enables ABL Diagnostics to market CDL Pharma’s clinical sample management and logistics services globally, alongside its own product offerings. This collaboration is essential for providing a comprehensive end-to-end pathway from clinical sample management to advanced molecular analysis.
Expanding Operational Capacity
In the United States, ABL Diagnostics has expanded its operational capacity through its affiliate, AdvancedDx Biological Laboratories USA Inc. This expansion has fortified logistics and biobanking capabilities on the East Coast, specifically designed to support third-party clinical trials. The seamless integration with CDL Pharma for studies based in the U.S. enhances the overall service quality and efficiency.
Advancements in Oncology Collaborations
CDL Pharma has also announced new partnerships in digestive oncology, which involve multi-year and multi-center clinical operations. These collaborations highlight the scalability and quality of CDL’s sample logistics and administrative management across complex, pan-European study footprints. Such advancements bolster the Group’s capability to manage diverse clinical operations effectively.
Commitment to Compliance and Quality
As part of the renewal process, the combined ABL Diagnostics and CDL services underwent a thorough audit to ensure compliance with regulatory standards. This review included an evaluation of quality system alignment and specific components like the Security Assurance Plan. The documentation from these reviews is maintained internally for future regulatory and sponsor audits, reflecting the Group’s commitment to high standards.
ISO Certification and Operational Reliability
CDL Pharma operates under an ISO 9001:2015-certified quality management system, aligned with international clinical research standards (ICH-GCP). This certification underscores the Group’s dedication to reliable operations and consistent quality in clinical research activities, thereby enhancing trust with partners and stakeholders.
Leadership Insights
Chalom Sayada, President & CEO of ABL Diagnostics and CDL Pharma, remarked, “Securing multi-year service continuity with a long-standing Pharma partner validates our model: industrial-grade kit design, logistics, and data management.” This model simplifies execution, compresses timelines, and ensures tailored project management for sponsors, ultimately leading to consistent molecular outputs.
Enhancing Customer Experience
Mohamed Erraffyqy, Head of Customer Experience & Service Excellence at ABL Diagnostics, noted the positive impact of U.S. logistics expansion and new European oncology collaborations on the company’s growth. He highlighted the increasing attach rates for their solutions, which support the generation of recurring revenues in the years ahead.
Broadening Molecular Diagnostics Portfolio
ABL Diagnostics specializes in innovative molecular biology tests, offering a wide range of products that include polymerase chain reaction (PCR) detection and DNA sequencing. The company markets its extensive product line globally through its sales team and a network of exclusive distributors. Their customer base includes academic clinical pathology laboratories, private reference laboratories, and researchers seeking robust microbiological content.
Innovative Product Offerings
The company’s expanding portfolio includes advanced detection solutions for various viral and bacterial targets, as well as comprehensive assays that cater to a diverse range of microbiological applications. Noteworthy products encompass HIV drug resistance testing, SARS-CoV-2 detection solutions, and microbiome analyses.
Integrated Solutions for Healthcare
ABL Diagnostics also provides integrated solutions, such as real-time syndromic PCR tests and clinical sample collection kits. Their patient medical record system, Nadis®, is utilized in over 200 hospitals in France for managing HIV and hepatitis cases. Such innovations reinforce ABL’s commitment to enhancing healthcare delivery through advanced molecular diagnostics.
Conclusion
The multi-year renewal between ABL Diagnostics, CDL Pharma, and Servier marks a significant milestone in clinical services, reinforcing operational reliability and expanding service capabilities. This collaboration not only enhances revenue visibility but also sets a firm foundation for future innovations in molecular diagnostics. As the landscape of healthcare and clinical research continues to evolve, such strategic partnerships will play a pivotal role in driving advancements and improving patient outcomes.
- ABL Diagnostics and CDL Pharma have renewed their services with Servier.
- The partnership enhances revenue visibility and operational capacity.
- New collaborations in oncology demonstrate scalability and quality.
- Comprehensive audits ensure compliance with regulatory standards.
- ABL’s innovative product offerings cater to diverse healthcare needs.
Read more → www.palmbeachpost.com